PROs From ASCENT-04 Study of Sacituzumab Govitecan Plus Pembrolizumab in First-Line TNBC

Laura Huppert, MD, highlights patient-reported outcomes from the phase 3 ASCENT-04 trial which compared first-line treatment with the antibody-drug conjugate sacituzumab govitecan plus the PD-1 inhibitor pembrolizumab vs pembrolizumab plus chemotherapy in patients with PD-L1–positive advanced triple-negative breast cancer. Huppert discusses specific PROs and their impact on quality of life, along with the overall significance of PRO data in fully understanding patients’ experience with specific treatments.